Austin Lammers1, Christopher G Slatore2, Erik K Fromme3, Kelly C Vranas4, Donald R Sullivan5. 1. Department of Hematology and Medical Oncology, Kaiser Permanente, Lafayette, Colorado; Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon. 2. VA Portland Health Care System (VAPORHCS), Health Services Research & Development, Portland, Oregon; Oregon Health and Science University, Pulmonary and Critical Care Medicine, Portland, Oregon; VAPORHCS, Section of Pulmonary and Critical Care Medicine, Portland, Oregon; Cancer Prevention and Control Program, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon. 3. Serious Illness Care Program, Ariadne Labs, Boston, Massachusetts; Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, Massachusetts. 4. VA Portland Health Care System (VAPORHCS), Health Services Research & Development, Portland, Oregon; Oregon Health and Science University, Pulmonary and Critical Care Medicine, Portland, Oregon; Cancer Prevention and Control Program, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon. 5. VA Portland Health Care System (VAPORHCS), Health Services Research & Development, Portland, Oregon; Oregon Health and Science University, Pulmonary and Critical Care Medicine, Portland, Oregon; Cancer Prevention and Control Program, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon. Electronic address: sullivad@ohsu.edu.
Abstract
INTRODUCTION: Patients with advanced lung cancer have a poor prognosis, but both chemotherapy and early palliative care (EPC) have been shown to improve survival and quality of life (QOL). The relationship between palliative care and receipt of chemotherapy receipt is understudied. We sought to determine if EPC is associated with chemotherapy receipt and intensity among patients with advanced stage lung cancer. METHODS: Retrospective cohort study of patients in the national Veterans Health Administration (VA) with stage IIIB or IV lung cancer diagnosed between January 2007- December 2013. EPC was defined as a specialist-delivered palliative care received within 90 days of cancer diagnosis. Outcomes included any chemotherapy receipt and high-intensity chemotherapy receipt defined as: i) more than 4 cycles of a platinum-based doublet, ii) ≥3 lines of chemotherapy, iii) Bevacizumab/Cetuximab triplet therapy, iv) Erlotinib use prior to 2011, and v) chemotherapy in the last days of life. Logistic regression was used to determine the association between EPC and chemotherapy receipt after adjustment for patient and tumor characteristics. RESULTS: Among the entire cohort (N=23,566), 37% received EPC and 45% received any chemotherapy. Among those with EPC, 34% received chemotherapy compared to 51% among those without EPC (Adjusted Odds Ratio (AOR=0.55, 95% CI: 0.51-0.58). Patients who received EPC had reduced receipt of high-intensity chemotherapy including >4 cycles of platinum-based doublet (AOR=0.68, 95% CI: 0.60-0.77), ≥ 3 lines of chemotherapy (AOR=0.61, 95% CI: 0.53-0.71), triplet therapy (AOR=0.68, 95% CI: 0.56-0.82) and use of erlotinib prior to 2011 (AOR=0.66, 95% CI: 0.55-0.79). Patients with EPC were more likely to receive chemotherapy in the last 14 (AOR=1.65, 95% CI: 1.44-1.87) and 30 days (AOR=1.67, 95% CI: 1.51-1.85) of life compared to those without EPC. CONCLUSIONS: EPC was associated with reduced receipt of both any chemotherapy and high-intensity chemotherapy. However, receipt of chemotherapy at the very end-of-life was increased among patients with EPC compared to those without EPC. Among patients with advanced lung cancer, EPC may optimize patient selection for chemotherapy receipt leading to reduced use of high-intensity therapy by focusing on quality of life in accordance with patients' performance, preferences and goals of care.
INTRODUCTION:Patients with advanced lung cancer have a poor prognosis, but both chemotherapy and early palliative care (EPC) have been shown to improve survival and quality of life (QOL). The relationship between palliative care and receipt of chemotherapy receipt is understudied. We sought to determine if EPC is associated with chemotherapy receipt and intensity among patients with advanced stage lung cancer. METHODS: Retrospective cohort study of patients in the national Veterans Health Administration (VA) with stage IIIB or IV lung cancer diagnosed between January 2007- December 2013. EPC was defined as a specialist-delivered palliative care received within 90 days of cancer diagnosis. Outcomes included any chemotherapy receipt and high-intensity chemotherapy receipt defined as: i) more than 4 cycles of a platinum-based doublet, ii) ≥3 lines of chemotherapy, iii) Bevacizumab/Cetuximab triplet therapy, iv) Erlotinib use prior to 2011, and v) chemotherapy in the last days of life. Logistic regression was used to determine the association between EPC and chemotherapy receipt after adjustment for patient and tumor characteristics. RESULTS: Among the entire cohort (N=23,566), 37% received EPC and 45% received any chemotherapy. Among those with EPC, 34% received chemotherapy compared to 51% among those without EPC (Adjusted Odds Ratio (AOR=0.55, 95% CI: 0.51-0.58). Patients who received EPC had reduced receipt of high-intensity chemotherapy including >4 cycles of platinum-based doublet (AOR=0.68, 95% CI: 0.60-0.77), ≥ 3 lines of chemotherapy (AOR=0.61, 95% CI: 0.53-0.71), triplet therapy (AOR=0.68, 95% CI: 0.56-0.82) and use of erlotinib prior to 2011 (AOR=0.66, 95% CI: 0.55-0.79). Patients with EPC were more likely to receive chemotherapy in the last 14 (AOR=1.65, 95% CI: 1.44-1.87) and 30 days (AOR=1.67, 95% CI: 1.51-1.85) of life compared to those without EPC. CONCLUSIONS: EPC was associated with reduced receipt of both any chemotherapy and high-intensity chemotherapy. However, receipt of chemotherapy at the very end-of-life was increased among patients with EPC compared to those without EPC. Among patients with advanced lung cancer, EPC may optimize patient selection for chemotherapy receipt leading to reduced use of high-intensity therapy by focusing on quality of life in accordance with patients' performance, preferences and goals of care.
Authors: Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour Journal: N Engl J Med Date: 2005-07-14 Impact factor: 91.245
Authors: Donald R Sullivan; Christopher W Forsberg; Linda Ganzini; David H Au; Michael K Gould; Dawn Provenzale; Christopher G Slatore Journal: J Clin Oncol Date: 2016-10-31 Impact factor: 44.544
Authors: Craig C Earle; Bridget A Neville; Mary Beth Landrum; John Z Ayanian; Susan D Block; Jane C Weeks Journal: J Clin Oncol Date: 2004-01-15 Impact factor: 44.544
Authors: Kirsten Wentlandt; Monika K Krzyzanowska; Nadia Swami; Gary M Rodin; Lisa W Le; Camilla Zimmermann Journal: J Clin Oncol Date: 2012-10-29 Impact factor: 44.544
Authors: Peter Goldstraw; Kari Chansky; John Crowley; Ramon Rami-Porta; Hisao Asamura; Wilfried E E Eberhardt; Andrew G Nicholson; Patti Groome; Alan Mitchell; Vanessa Bolejack Journal: J Thorac Oncol Date: 2016-01 Impact factor: 15.609
Authors: C von Plessen; B Bergman; O Andresen; R M Bremnes; S Sundstrom; M Gilleryd; R Stephens; J Vilsvik; U Aasebo; S Sorenson Journal: Br J Cancer Date: 2006-10-03 Impact factor: 7.640
Authors: O P Geerse; D Brandenbarg; H A M Kerstjens; A J Berendsen; S F A Duijts; H Burger; G A Holtman; J E H M Hoekstra-Weebers; T J N Hiltermann Journal: Lung Cancer Date: 2019-02-10 Impact factor: 5.705